Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...

Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China ORLANDO, Fla., April 11, 2025 (GLOBE ...

Love Pharma has struck a deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/1b304d/the_top_50_transde) has announced the addition of the "The Top 50 ...

BROOMALL, Pa., May 30, 2012--Transdermal Specialties Inc., a pioneer in painless, injection-free ultrasonic transdermal drug-delivery systems for the pharmaceutical industry, will unveil its ...

Companies ally on preclinical and clinical development. Altea Therapeutics entered into a partnership with KAI Pharmaceuticals for the preclinical and clinical development of certain KAI peptides ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...